628 Views

Instructional Course

Instructional Course - Available with the Platinum and Silver packages or Individual Course Ticket

088IC - Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems

Monday, May 16, 2022

1:30 PM – 3:30 PM

Location: Room 219

Instructional Course Director(s)

KP

Kamal S. Pohar, MD

The Ohio State University

Instructional Course Faculty(s)

Ashish M. Kamat, MD, MBBS, FACS

MD Anderson Cancer Center
FW

Fred A. Witjes, MD, PhD

Professor of Urology
Radboud University Medical Center
Cheryl Taylore Lee, MD

Professor of Urology
The Ohio State University

Learning Objectives:

Implement current practice guidelines into the office setting and explain methods and resources to improve transurethral resection of a bladder tumor (TURBT) skills.
Identify the best intravesical agent and duration of therapy for low, intermediate, and high risk settings and what to do during a BCG shortage.
Identify methods to treat significant toxicities from various intravesical therapies.
Define high risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.
Identify the scientific rationale for investigating immune oncology agents for BCG unresponsive disease and become familiar with current clinical trial designs.

1. The attendee will be able to implement current practice guidelines into the office setting.
2. The attendee will be able to identify the best intravesical agent and duration of therapy for low, intermediate and high risk non-muscle invasive bladder cancer (NMIBC) and what to do during a bacillus Calmette-Guérin (BCG) shortage.
3. Identify methods to treat significant toxicities from various intravesical therapies.
4. Define high risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.
5. Understand the scientific rationale for investigating immune and targeted therapies for BCG unresponsive disease.